3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Prostatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
aldesleukin
43
Sunitinib
42
Cyclophosphamide
30
Nivolumab
29
pembrolizumab
27
Everolimus
27
Interferon-alpha
25
Bevacizumab
23
Sorafenib
22
Interleukin-2
20
fludarabine phosphate
19
Radiotherapy
18
Ipilimumab
18
Filgrastim
18
Axitinib
18
Gene Expression Profiling
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
Radiosurgery
13
fludarabine
11
Doxorubicin
11
Carboplatin
11
Blood Specimen Collection
11
temsirolimus
10
atezolizumab
9
Immunohistochemistry
9
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Phlebotomy
×
Genitourinary
×
Clear all
NCT04154163
2022-02-28
ADOPT
University of Dundee
Completed
18 enrolled